This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lynn D. Kramer, MD
Wallace Laboratories Half Acre Road Cranbury, NJ 08512

Arch Neurol. 1990;47(10):1059.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Sotelo et al^1,2 report clinical trials comparing albendazole with praziquantel as therapy for neurocysticercosis. In a trial of very similar design, Alarcon et al³ compared two dosing schedules of albendazole. These trials "randomly allocated" 25¹ or 23² subjects to one of three groups. The active drug treatment groups were of equal size in both trials, with 10¹ or nine² subjects in each treatment group, and the control (no treatment) group had five subjects in each trial. The outcome variable evaluated was the change in cyst size as demonstrated by computed tomography. These reports are illustrative of the ills replicated in clinical trials touting various pharmacologic regimens in the treatment of neurocysticercosis. In these and other putatively seminal clinical trials in this disorder, several easily identified problems limit the utility of the data. The interpretation of these trials is particularly important, given . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?